Then, now, and down the road: Trends in pharmaceutical patent settlements after FTC v. Actavis
Last week, Bureau of Competition staff published a report on filings received in fiscal year (FY) 2016 under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), the thirteenth such report since the MMA took effect in 2004. These reports identify the frequency of pharmaceutical patent settlements and specific types of provisions that appear in such settlements. Comparing the data in these reports with developments in...